About Theraclion
Theraclion is a company based in Malakoff (France) founded in 2004. Theraclion has raised $4.5 million across 6 funding rounds from investors including Natixis, European Union and Inner Mongolia Furui Medical Science. Theraclion offers products and services including SONOVEIN, ECHOPULSE, and EPack. Theraclion operates in a competitive market with competitors including Insightec, HistoSonics, Profound Medical, Carthera and SONIRE Therapeutics, among others.
- Headquarter Malakoff, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$4.24 M (USD)187as on Dec 31, 2023
-
Net Profit
-$3.98 M (USD)26as on Dec 31, 2023
-
EBITDA
-$5.31 M (USD)20as on Dec 31, 2023
-
Total Equity Funding
$4.5 M (USD)
in 6 rounds
-
Latest Funding Round
$10.57 M (USD), Post-IPO
Jul 23, 2016
-
Investors
Natixis
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Theraclion
Theraclion offers a comprehensive portfolio of products and services, including SONOVEIN, ECHOPULSE, and EPack.
Non-invasive device for treating varicose veins using focused ultrasound.
Non-invasive system for thyroid nodules and breast fibroadenoma treatments.
Supportive component for echotherapy platforms in medical applications.
Funding Insights of Theraclion
Theraclion has successfully raised a total of $4.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10.57 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Theraclion
Theraclion has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Natixis, European Union and Inner Mongolia Furui Medical Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Locked | Locked | Locked | |
|
Therapeutic and diagnostic solutions for liver diseases are provided.
|
Locked | Locked | Locked | |
|
Diversified investment management services are provided globally by Aviva Investors.
|
Locked | Locked | Locked |
Investor details for Theraclion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Theraclion
Investment portfolio details for Theraclion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Theraclion
Detailed financials for Theraclion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Theraclion Comparisons
Peer comparison for Theraclion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Theraclion
Theraclion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insightec, HistoSonics, Profound Medical, Carthera and SONIRE Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided.
|
|
| Locked | Locked | Locked |
Tissue ablation is achieved through non-invasive ultrasound Histotripsy technology.
|
|
| Locked | Locked | Locked |
Image-guided prostate ablation systems for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Ultrasound-based medical devices for brain tumor treatment are developed.
|
|
| Locked | Locked | Locked |
High-intensity focused ultrasound systems for targeted cancer treatments are developed.
|
Detailed competitors of Theraclion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Theraclion
Complete news archive for Theraclion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Theraclion
Theraclion was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Theraclion is headquartered in Malakoff, France. It is registered at Malakoff, Ile-de-france, France.
Martin Deterre is the current CEO of Theraclion.
Theraclion is a funded company, having raised a total of $4.5M across 6 funding rounds to date.
Annual revenue of Theraclion is $4.24M as on Dec 31, 2023.
Theraclion was founded in 2004 and is headquartered in Malakoff, France. Operations focus on the medical device sector, where non-invasive robotic platforms using high-intensity focused ultrasound (HIFU) guided by real-time monitoring are developed. Sonovein is utilized for thermal ablation of varicose veins, while Echopulse targets thyroid nodules and breast fibroadenomas without surgical intervention. These systems enable treatments free of incisions, scars, or anesthesia.
Theraclion's top competitors include Insightec, HistoSonics and Profound Medical.
Theraclion offers SONOVEIN, ECHOPULSE, and EPack.
Theraclion has 5 investors. Key investors include Natixis, European Union, Inner Mongolia Furui Medical Science, Aviva Investors, and Truffle Capital.